Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 12.43M P/E - EPS this Y - Ern Qtrly Grth -
Income -7.2M Forward P/E - EPS next Y - 50D Avg Chg -16.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book 1.78 EPS next 5Y - 52W High Chg -99.00%
Recommedations - Quick Ratio 1.69 Shares Outstanding 2.95M 52W Low Chg 8.00%
Insider Own 41.62% ROA -61.69% Shares Float 1.36M Beta 1.04
Inst Own 1.73% ROE -186.00% Shares Shorted/Prior 85.80K/20.80K Price 0.90
Gross Margin - Profit Margin - Avg. Volume 1,508,429 Target Price -
Oper. Margin - Earnings Date - Volume 66,192 Change -1.09%
About Shuttle Pharmaceuticals Holding

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

Shuttle Pharmaceuticals Holding News
11/13/24 Shuttle Pharma Provides Third Quarter 2024 Corporate Update
10/29/24 Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
10/29/24 Shuttle Pharma Pays Off Senior Secured Convertible Note
10/29/24 Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/28/24 Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/28/24 Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
09/16/24 Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
09/11/24 Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
09/05/24 Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
09/04/24 Shuttle Pharma Provides Second Quarter 2024 Corporate Update
08/28/24 Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
08/26/24 Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
08/14/24 Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
07/19/24 Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
06/18/24 Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
05/22/24 Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
05/14/24 Shuttle Pharma Provides First Quarter 2024 Corporate Update
04/29/24 Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
04/23/24 Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
04/03/24 Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
SHPH Chatroom

User Image marianaparra Posted - 1 day ago

$SHPH not bullish nor bearish , this is the perfect example of manipulation , pumping for a few days on great news just to dump it right back , if you're lucky to catch both the bottom and the TOP , you're the greatest motherf@ker , otherwise just sit around and watch . In order to avoid delisting they need more good news or another reverse split , first would be awesome the other one not so much ...

User Image ragingbull22 Posted - 2 days ago

$SHPH G A R B A G E!

User Image First_Class_Seaman Posted - 4 days ago

$ZONE BULL SENTIMENT JUST WENT THROU THE ROOF $SHPH Bleeding 🩸

User Image NewsAndFilings Posted - 6 days ago

Yesterday's Recap: $SHPH Third Quarter 2024 Update $AURI NFT and Crypto Currency Products $UTRX Cryptocurrency Portfolio Strategy $VAPR eliminating over 90% of related party payables $CBMJ Launches Shopping Channel to 30 Million Samsung TVs

User Image MsGrumpy Posted - 6 days ago

$SHPH Shuttle Pharma Third Quarter 2024 Corporate Update https://www.globenewswire.com/news-release/2024/11/13/2980735/0/en/Shuttle-Pharma-Provides-Third-Quarter-2024-Corporate-Update.html

User Image Giants67 Posted - 6 days ago

$SHPH Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2024. https://www.globenewswire.com/news-release/2024/11/13/2980735/0/en/Shuttle-Pharma-Provides-Third-Quarter-2024-Corporate-Update.html

User Image NewsAndFilings Posted - 6 days ago

$SHPH Shuttle Pharma Provides Third Quarter 2024 Corporate Update https://www.globenewswire.com/news-release/2024/11/13/2980735/0/en/Shuttle-Pharma-Provides-Third-Quarter-2024-Corporate-Update.html

User Image 7SamuraiScalper Posted - 1 week ago

$SHPH out $1.19....have been breaking even on lots of dumb plays

User Image MorenitaScorp Posted - 1 week ago

$SHPH ⌚️

User Image 7SamuraiScalper Posted - 1 week ago

$SHPH Just got some at $1.19. I know......but pretty slaughtered....if there are degrees of that....NFA

User Image monkeyhustle55 Posted - 1 week ago

$SHPH Ropidoxuridine, an innovative drug being developed by Shuttle Pharmaceuticals, incorporates modified pyrimidine structures to enhance the efficacy of radiotherapy. Pyrimidines are one of the fundamental building blocks of DNA and RNA, and by altering their structure, researchers can create compounds that interact with DNA in ways that disrupt cancer cell proliferation. Here’s how ropidoxuridine’s mechanism may work: Pyrimidine Modification: Pyrimidines are essential components in DNA that contribute to genetic stability and cellular function. By modifying these molecules, ropidoxuridine can integrate into the DNA of cancer cells during replication. This modified incorporation makes cancer cells more susceptible to radiation-induced damage because the altered DNA structure increases the likelihood of breakage when exposed to ionizing radiation. Epigenetic-Like Gene Regulation: Although ropidoxuridine directly integrates into DNA, its effects extend beyond simple DNA disruption.

User Image sunburned1 Posted - 1 week ago

$SHPH

User Image RRCORNER Posted - 1 week ago

$SHPH Ropidoxuridine trials will expand to other indications but the normal pathway is to focus on one indication such as GBM knowing that upon the first approval for GBM, the industry will immediately begin using it as "Off Label" for ALL OTHER INDICATIONS. I believe SHPH will soar from its current extremely low market cap and surprise very big. This could be a real game changer in cancer treatment.

User Image justiceforb_85 Posted - 1 week ago

$SHPH what happened to ropidoxuridine development in GI cancers? Also, do we have any data for its efficacy in glioblastoma?

User Image Hawaiianinvesta Posted - 1 week ago

$SHPH i'm in! let's do it!

User Image robanbieber Posted - 1 week ago

$SHPH done. dropping this bag now... glta...

User Image dartgator Posted - 1 week ago

$SHPH hopefully the bleeding has stopped for good!

User Image dartgator Posted - 2 weeks ago

$SHPH it’s due for a pop sooner or later!

User Image marianaparra Posted - 2 weeks ago

$SHPH I would really like to know who's selling now ?! yesterday shorts got to return over 300k shares , the only answer would be insiders , but why here at $1.3-1.4 ?!

User Image sunburned1 Posted - 2 weeks ago

$SHPH

User Image kemsma62 Posted - 2 weeks ago

$SHPH Very weird! 🤔

User Image cob7178 Posted - 2 weeks ago

$SHPH Out of gas

User Image kemsma62 Posted - 2 weeks ago

$SHPH We need some good news again to get this fly! 🚀💥

User Image c319419 Posted - 2 weeks ago

$EVOK $GLUE $MNPR $RGC $SHPH Anyone can make calls after the fact, your a phony!

User Image kemsma62 Posted - 2 weeks ago

$SHPH What’s going on here? 🤔 🧐

User Image MarketMasterMind Posted - 2 weeks ago

$SHPH watching for entry 🤑Ⓜ️

User Image ANTHONYMOMO Posted - 2 weeks ago

$RGC $EVOK $MNPR $GLUE $SHPH

User Image NewsAndFilings Posted - 2 weeks ago

Weekly Rundown: $SHPH Public Offering, Pays off Debt & First Patients in Phase 2 Clinical Trial $CANB Company Reorganization With Nascent Pharma Holdings $RJDG Two Multifamily Contracts $LVVV s Launches Online Sales Portal $INTV Partnership with Driptide Wellness

User Image c319419 Posted - 2 weeks ago

$EVOK $GLUE $MNPR $RGC $SHPH Just another fake one trying to take credit for calling stocks after they have already popped.

User Image ANTHONYMOMO Posted - 2 weeks ago

My TOP calls for last WEEK (part - 1- ) were : 1- $MNPR 4.90 - 21.95 2- $EVOK 5.43 - 17.39 3- $GLUE 4.90 - 12.40 4- $RGC 4.99 - 12.50 5- $SHPH 1.36 - 2.41 Everyday I have two alerts here on STOCKTWITS. FIRST : 08: 30 am Eastern Time (ET) SECOND : 13: 00 pm Eastern Time (ET)

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Brown Milton Director Director Dec 13 Sell 0.4632 2,921 1,353 1,094,610 01/02/24
Jacobs Bette Director Director Dec 13 Sell 0.4632 4,157 1,926 27,064 12/20/23
Dritschilo Anatoly CEO and Chairman CEO and Chairman Dec 29 Sell 1.605 8,372 13,437 1,085,200 01/03/23
Rich Tyvin Chief Medical Office.. Chief Medical Officer Dec 29 Sell 1.605 1,414 2,269 2,429 01/03/23
Jung Mira Chief Scientific Off.. Chief Scientific Officer Dec 29 Sell 1.605 328 526 1,071,388 01/03/23
Jacobs Bette Director Director Dec 29 Sell 1.605 4,366 7,007 31,221 01/03/23
Dritschilo Peter President and COO President and COO Dec 29 Sell 1.605 3,820 6,131 6,560 12/30/22